Polypharmacology: Challenges and Opportunities in Drug Discovery

被引:801
作者
Anighoro, Andrew [1 ]
Bajorath, Juergen [2 ]
Rastelli, Giulio [1 ]
机构
[1] Univ Modena & Reggio Emilia, Dept Life Sci, Via Campi 183, I-41125 Modena, Italy
[2] Univ Bonn, LIMES Program Unit Chem Biol & Med Chem, B IT, Dept Life Sci Informat, D-53113 Bonn, Germany
关键词
PROTEIN-COUPLED RECEPTORS; PHASE-I TRIALS; KINASE INHIBITORS; SYSTEMATIC IDENTIFICATION; COMBINATION THERAPIES; HSP90; INHIBITORS; PARP INHIBITORS; ANTI-TARGETS; CANCER; PHARMACOLOGY;
D O I
10.1021/jm5006463
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
At present , the legendary magic bullet, ie, a drug with high potency and selectivity toward a specific biological target, shares the spotlight with an emerging and alternative polypharmacology approach. Polypharmacology suggests that more effective drugs can be developed by specifically modulating multiple targets. It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches. In this respect, a drug that hits multiple sensitive nodes belonging to a network of interacing targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs. In this review, we will compare advantages and disadvantages of multitarget versus combination therapies, discuss-potential drug promiscuity arising from off-target effects, comment on drug repurposing and introduce approaches to the computational design of multitarget drugs.
引用
收藏
页码:7874 / 7887
页数:14
相关论文
共 90 条
[1]   A Mapping of Drug Space from the Viewpoint of Small Molecule Metabolism [J].
Adams, James Corey ;
Keiser, Michael J. ;
Basuino, Li ;
Chambers, Henry F. ;
Lee, Deok-Sun ;
Wiest, Olaf G. ;
Babbitt, Patricia C. .
PLOS COMPUTATIONAL BIOLOGY, 2009, 5 (08)
[2]   Insights towards sulfonamide drug specificity in α-carbonic anhydrases [J].
Aggarwal, Mayank ;
Kondeti, Bhargav ;
McKenna, Robert .
BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (06) :1526-1533
[3]  
Altieri DC, 2010, FUTURE ONCOL, V6, P487, DOI [10.2217/fon.10.26, 10.2217/FON.10.26]
[4]  
Altschul SE, 1997, THEORETICAL AND COMPUTATIONAL METHODS IN GENOME RESEARCH, P1
[5]  
Anighoro A., 2013, CHIM IND, V4, P105
[6]   Enrichment Factor Analyses on G-Protein Coupled Receptors with Known Crystal Structure [J].
Anighoro, Andrew ;
Rastelli, Giulio .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2013, 53 (04) :739-743
[7]   Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases [J].
Apsel, Beth ;
Blair, Jimmy A. ;
Gonzalez, Beatriz ;
Nazif, Tamim M. ;
Feldman, Morri E. ;
Aizenstein, Brian ;
Hoffman, Randy ;
Williams, Roger L. ;
Shokat, Kevan M. ;
Knight, Zachary A. .
NATURE CHEMICAL BIOLOGY, 2008, 4 (11) :691-699
[8]  
Azzaoui K, 2007, CHEMMEDCHEM, V2, P874, DOI 10.1002/cmdc.200700036
[9]   Navigating structure-activity landscapes [J].
Bajorath, Juergen ;
Peltason, Lisa ;
Wawer, Mathias ;
Guha, Rajarshi ;
Lajiness, Michael S. ;
Van Drie, John H. .
DRUG DISCOVERY TODAY, 2009, 14 (13-14) :698-705
[10]   Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure [J].
Bender, Andreas ;
Scheiber, Josef ;
Glick, Meir ;
Davies, John W. ;
Azzaoui, Kamal ;
Hamon, Jacques ;
Urban, Laszlo ;
Whitebread, Steven ;
Jenkins, Jeremy L. .
CHEMMEDCHEM, 2007, 2 (06) :861-873